Second-Generation TKIs May Be Effective After First-Line Imatinib Failure in Pediatric CML

There is a paucity of data on the use of second-generation tyrosine kinase inhibitors among pediatric patients with chronic-phase chronic myeloid leukemia.

from Latest articles from Cancer Therapy Advisor Hematologic Cancers https://ift.tt/2Mwt1R7